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Sébastien Denys o, Annie St-Amand p, Shoji F. Nakayama q, Tiina Santonen r, Robert Barouki s, 
Robert Pasanen-Kase t, Hans G.J. Mol u, Theo Vermeire a, Kate Jones v, Maria João Silva w,x, 
Henriqueta Louro w,x, Hilko van der Voet y, Radu-Corneliu Duca z,aa, Hans Verhagen ab,ac, 
Cristina Canova ad, Jacob van Klaveren a, Marike Kolossa-Gehring ae, Jos Bessems f 
a National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands 
b Environmental Health Behaviour Lab, Instituto de Saúde Ambiental, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal 
c Quantitative Sustainability Assessment, Department of Technology, Management and Economics, Technical University of Denmark, Produktionstorvet 424, 2800, Kgs. 
Lyngby, Denmark 
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A B S T R A C T   
Data generated by the rapidly evolving human biomonitoring (HBM) programmes are providing invaluable 
opportunities to support and advance regulatory risk assessment and management of chemicals in occupational 
and environmental health domains. However, heterogeneity across studies, in terms of design, terminology, 
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biomarker nomenclature, and data formats, limits our capacity to compare and integrate data sets retrospectively 
(reuse). Registration of HBM studies is common for clinical trials; however, the study designs and resulting data 
collections cannot be traced easily. We argue that an HBM Global Registry Framework (HBM GRF) could be the 
solution to several of challenges hampering the (re)use of HBM (meta)data. The aim is to develop a global, host- 
independent HBM registry framework based on the use of harmonised open-access protocol templates from 
designing, undertaking of an HBM study to the use and possible reuse of the resulting HBM (meta)data. This 
framework should apply FAIR (Findable, Accessible, Interoperable and Reusable) principles as a core data 
management strategy to enable the (re)use of HBM (meta)data to its full potential through the data value chain. 
Moreover, we believe that implementation of FAIR principles is a fundamental enabler for digital transformation 
within environmental health. 
The HBM GRF would encompass internationally harmonised and agreed open access templates for HBM study 
protocols, structured web-based functionalities to deposit, find, and access harmonised protocols of HBM studies. 
Registration of HBM studies using the HBM GRF is anticipated to increase FAIRness of the resulting (meta)data. It 
is also considered that harmonisation of existing data sets could be performed retrospectively. As a consequence, 
data wrangling activities to make data ready for analysis will be minimised. In addition, this framework would 
enable the HBM (inter)national community to trace new HBM studies already in the planning phase and their 
results once finalised. The HBM GRF could also serve as a platform enhancing communication between scientists, 
risk assessors, and risk managers/policy makers. The planned European Partnership for the Assessment of Risk 
from Chemicals (PARC) work along these lines, based on the experience obtained in previous joint European 
initiatives. Therefore, PARC could very well bring a first demonstration of first essential functionalities within the 
development of the HBM GRF.   
1. Introduction 
Human biomonitoring (HBM) is defined as the method for assessing 
human exposure to chemicals or their effects by measuring chemicals, 
their metabolites or reaction products (and/or their effects biomarkers) 
in human specimens (WHO, 2015a). HBM is a valuable tool to support 
the environment and health policy-making process because it provides 
quantitative actual distribution of exposures in a population. Environ-
mental pollutants can then be mapped for emerging pollutants, as well 
as data regarding their resulting health effects, and/or population 
susceptibility. 
HBM has a long history serving health surveys with well-known 
national programs such as the German Environmental Surveys 
(GerES), the US National Health and Nutrition Examination Survey 
(NHANES), the Canadian Health Measures Survey (CHMS), and the 
Korean National Environmental Health Survey (KoNEHS). (Becker et al., 
2003; Choi et al., 2017; Cox, 1992; Haines et al., 2017). However, only 
recently HBM has become more widely used in risk assessment and 
management frameworks. HBM is considered the “gold standard” for 
assessing people’s exposure to environmental chemical agents (Sexton 
et al., 2004). The increased availability of exposure and effect bio-
markers is helping HBM to become an even more valuable tool to 
investigate associations between internal exposures and health out-
comes. This approach presents well-known complementary information 
on and advantages over cell-based and experimental animal studies 
(Burns et al., 2019; Mustieles and Fernández, 2020). In the current 
article, we define HBM studies as “all observational studies that apply 
HBM as a tool to collect data” (WHO, 2015a). These might include 
studies where the main scope is a health survey, health surveillance, as 
well as biomonitoring programmes in both general and occupational 
populations. 
HBM research in combination with results from human and/or ani-
mal toxicological studies, for example in the form of hypothesized 
Adverse Outcome Pathway (AOP) networks or the use of biomonitoring 
equivalents, can provide interpretation tools for human hazard and risk 
assessment (Baken et al., 2019; Faure et al., 2020; Mustieles et al., 2020; 
St-Amand et al., 2014; Zare Jeddi et al., 2020). Moreover, HBM provides 
a holistic perspective, enabling an integrative measurement of combined 
exposures from all routes (ingestion, inhalation, and dermal uptake) and 
all environmental sources (air, water, soil, dust, food), the results of 
toxicokinetic processes and individual differences in combination with 
signs of (early) responses with effect biomarkers (Mustieles et al., 2020; 
Zare Jeddi et al., 2020). If combined with health surveys and cohorts, 
HBM (meta)data can also provide opportunities to investigate the rela-
tionship between internal exposure and health effects, promote 
risk-reduction measures, monitor exposure trends, and evaluate the 
effectiveness of implemented national and global policies (e.g., (Eykel-
bosh et al., 2018; Romano et al., 2020)). Overall, the use of HBM (meta) 
data increases the value of exposure information in risk assessment and 
management context (Wilhelm, 2020). 
Given the multiple benefits of using HBM at national and global 
levels, the use of HBM is a recognized priority in chemical safety. HBM 
can increase the robustness of regulatory long-term decisions for mar-
keted chemicals, and in particular, the increased importance of mixture 
risk assessment of chemicals and grouping approaches, as echoed at 
national, supranational, and intergovernmental level such as UN, WHO, 
OECD and EU (EC, 2020a; OECD, 2018; SAICM, 2013; WHO, 2015b). To 
serve this role, methodologies should be harmonised and HBM (meta) 
data should be easily findable, accessible, interoperable, secure, shared 
and reused by default (EC, 2020a). 
Regrettably, HBM has received little regulatory application to date 
which is partly due to a lack of sufficient, reliable, quality-assured, and 
well-structured (meta)data. HBM is an important and useful tool, yet 
quite complicated in terms of its design, application, and interpretation. 
The existing legislative frameworks on chemicals do not currently pro-
vide clear harmonised guidance for developing a comprehensive and 
integrated assessment of (combined) internal exposures to chemicals 
from different sources and routes. Any available guidance has evolved 
separately in different regulatory frameworks (Bopp et al., 2018; 
Drakvik et al., 2020; Evans et al., 2016; Fantke et al., 2020a; Louro et al., 
2019). 
This article aims to describe the challenges and needs to drastically 
increase the use and possible reuse of HBM data. It describes re-
quirements to make HBM study information (metadata as wells as 
measurement data) more FAIR (Findable, Accessible, Interoperable, and 
Reusable) (Wilkinson et al., 2016). In this article, these four principles 
are grouped in the coupled cornerstones of findability/accessibility and 
interoperability/reusability. Findability/accessibility is a system to store 
HBM (meta)data. Interoperability/reusability is how the (meta)data 
themselves should be expressed (and stored in HBM data repositories). 
For both cornerstones, harmonisation is critical. Harmonisation of 
storage systems for HBM (meta)data helps to find and better access HBM 
(meta)data (better findability and quicker access) where harmonisation 
of the HBM (meta)data generation itself enables reuse and interopera-
bility. This article attempts to scrutinise whether a framework for 
harmonised, web-based HBM study registries, as so called HBM Global 
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Registry Framework (HBM GRF), could accommodate existing needs. 
2. Harmonisation and FAIRification of HBM studies, needs, 
challenges and opportunities 
Systematic harmonisation and FAIRification of HBM (meta)data 
production through the data value chain can improve all aspects of 
HBM. First, results from several HBM studies could be compared easier 
to delineate e.g., exposure patterns. This refers to challenges for instance 
regarding differences in the definition of age groups (teenagers e.g., 
10–18 years old or 13–19 years old), lifestyle parameters measured, 
biological matrices used, and of sampling methods, storage conditions as 
well as analytical procedures (Ågerstrand et al., 2018; Bocato et al., 
2019; Joas et al., 2012). Moreover, the metadata including information 
about the studies are not always readily available. Even when such data 
are accessible, data are often scattered and/or incomplete thereby 
undermining the proper understanding, interpretation, and final use of 
the HBM data collected to support chemical risk assessment. Second, it 
could facilitate performing combined (meta)analyses of data from 
different HBM studies, aiming for increased statistical power, to find e. 
g., correlations between exposure biomarkers and effect biomarkers to 
support exposure to outcome assessments (Boyden and Walnicki, 2021). 
The use of systematic reviews and (meta)analyses is gaining acceptance 
in exposure science to transparently synthesize and evaluate a body of 
scientific evidence to answer research or policy questions (Hubal, 2019; 
Wikoff et al., 2020; Wolffe et al., 2019). Nevertheless, handling and 
comparing heterogeneous data generated across multiple scientific dis-
ciplines is challenging. This is especially true when a high degree of 
variability across studies is expected in terms of study aims and designs, 
population characteristics, exposure assessment procedures, data anal-
ysis and reporting (Burns et al., 2019; Goodman et al., 2019; Hubal, 
2019). Third, it would also enable data sharing and data integration 
which are of particular relevance for decision making in environmental 
and occupational health policies (Kromerová and Bencko, 2019; Louro 
et al., 2019). It is clear that there is an increasing use purpose for HBM 
data in compliance to the FAIR (Findable, Accessible, Interoperable, 
Reusable) data principles. 
Currently, the abovementioned opportunities are unfortunately 
hindered by problems with data comparability due to lack of harmo-
nisation. Based on a survey regarding national practices in risk assess-
ment and risk assessors’ views on HBM use in Europe (Louro et al., 
2019), the European Human Biomonitoring Initiative HBM4EU1 
recognized that regulatory practices related to HBM still vary across 
different countries. HBM data should be collected using harmonised 
study protocols to a significant extent to facilitate data interpretation 
(Fiddicke et al., 2021). In addition, the need for harmonised coding of 
substances and metabolites measured and the statistical analysis such as 
aggregation of individual data to percentiles of a distribution of HBM 
levels has received particular attention under recent HBM research 
projects. Harmonised study designs and structured study registries could 
counter these problems. 
The HBM community would profit from global sharing of informa-
tion of existing, new, and planned HBM studies. The authors envisage 
that any registry system should be globally useable and legislative 
framework independent, be it national legislation such as in the USA, 
Canada, Japan, Korea, Germany, France, or regional legislations in the 
EU or a framework like the OECD. Given that, we hereby present the 
concept for a web-based system based on modern IT-technology and 
independent of any website host requirements as part of an overarching 
HBM GRF. 
The HBM GRF would facilitate and promote prospective (a priori) 
harmonisation of HBM study designs and thus the resulting HBM data 
would follow the FAIR data principals. As a consequence, data 
wrangling activities to make data ready for analysis will be minimised. 
Therefore, prospective (a priori) harmonisation of foreseen or already 
planned HBM studies is recommended rather than focusing on retro-
spective (post-hoc) harmonisation. The prospective (a priori) harmo-
nisation leads to a higher degree of data homogeneity in an effective 
way. It should be noted that aligning in terms of harmonisation is 
essential but is different from standardization. HBM is not science in the 
sense of duplicating experiments based on standardised methods. It is a 
tool for field studies where some parts obviously could be standardised 
in the future, such as analytical chemical methods while the process of 
defining study population and the sampling process can be harmonised 
but not standardised. The HBM GRF should facilitate a step-by-step 
harmonisation process but not necessarily standardization using a 
scientifically and technically sound and viable system. Fig. 1 provides a 
general overview of the HBM GRF concepts and potentials. 
3. Existing initiatives towards verification of HBM data 
Comparability and combination of results and interoperability of 
data are often difficult due to a lack of harmonisation, even when 
different HBM studies have investigated similar research questions (Joas 
et al., 2012; Lermen et al., 2020). In the last 10–15 years, significant 
efforts have been made towards harmonising HBM studies prospectively 
such as in the European Commission funded projects COPHES, DEMO-
COPHES and HBM4EU (Ganzleben et al., 2017) as well as the European 
Cooperation in Science and Technology (COST) Action DiMoPEx 
(DiMoPEx, 2015). Codebooks were developed for both the HBM expo-
sure data as well as accompanying variables important for interpretation 
(age, sex, gender, NUTS [Nomenclature of Territorial Units for Statis-
tics] codes, season of sampling, etc.) in a harmonised structure and 
format. Statistical analysis protocols scripted in R were used to extract 
comparable and machine-readable summary statistics or “aggregated 
data” that can be compared across data collections of the HBM4EU 
aligned studies and also across existing studies that share similarities in 
design. This has allowed the development of an interactive dashboard to 
display the data of the HBM4EU project (https://www.hbm4eu.eu/eu-h 
bm-dashboard/). Work on occupational exposure under the HBM4EU 
project is also directed to harmonise methodologies and data collection 
by developing standard operating procedures (SOPs), that can be used in 
multiple countries and analysed in an integrative approach (Santonen 
et al., 2019). 
Registries containing some (meta)data on HBM studies or studies 
containing an HBM part exist such as the WHO International Clinical 
Trials Registry Platform2, the US Clinical Trials database3. In addition, 
registries exist in which planned work is registered before the execution 
of the study. PROSPERO4 is an example of such an international data-
base of prospectively registered systematic reviews with a health-related 
outcome. Others such as the EU Clinical Trials Register5, already con-
tains human intervention studies. 
Moreover, there are several initiatives as listed in Table 1 regarding 
data collections containing mainly environmental monitoring and 
external exposure monitoring data. The Information Platform for 
Chemical Monitoring (IPCHEM6), the NORMAN network7, the Elixir 
community (ELIXIR, 2017), the BBMRI-ERIC8 and the Hazchem@work 
for occupational exposure data have been created to tackle the lack of 
harmonised information (EU, 2016). Most of these portals have their 
own challenges, some of which are highlighted in Table 1. In addition, 
1 https://www.hbm4eu.eu/. 
2 https://www.who.int/clinical-trials-registry-platform.  
3 https://clinicaltrials.gov/.  
4 https://www.crd.york.ac.uk/prospero/.  
5 https://www.clinicaltrialsregister.eu/.  
6 https://ipchem.jrc.ec.europa.eu/.  
7 https://www.norman-network.net.  
8 https://www.bbmri-eric.eu. 
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there are many health surveys and HBM studies at national, regional 
and/or international levels which are not typically integrated into these 
platforms despite their potential for enhancing informed decision 
making in environment, public and occupational health. 
IPCHEM was established by the European Commission (EC) to sup-
port a coordinated approach for collecting, storing, sharing, and 
assessing data on the occurrence of chemicals and chemical mixtures in 
humans and the environment. It is structured in four thematic modules: 
‘environmental monitoring’, ‘human biomonitoring’, ‘food and feed’ 
and ‘products and indoor air.’ IPCHEM is designed to specifically pro-
vide access to chemical monitoring data and underlying (meta)data 
currently not readily accessible, making them findable and accessible 
and to a certain extent interoperable and reusable (Comero et al., 2020; 
Knetsch and Ruether, 2016; Wilkinson et al., 2016). IPCHEM is intended 
to assist scientists and risk managers/policy makers to discover and 
access chemical monitoring data on existing, new, emerging and 
less-investigated chemicals, covering a wide range of matrices and 
media (Comero et al., 2020). It is however not intended to register study 
designs ex ante. IPCHEM is the European Commission’s reference access 
point for searching, accessing and retrieving chemical occurrence data 
collected and managed in Europe. IPCHEM is a distributed infrastruc-
ture. Data owners/data providers can decide on the level of detail to 
which the different IPCHEM user groups can access their data. As shown 
in Fig. 2, the volume of HBM datasets uploaded to the IPCHEM platform 
has increased by over 400% in the last two years. It includes now more 
than 100 (meta)data for HBM data collections gathered under the 
HBM4EU project (EC, 2020b). 
The platform already includes particularly useful (meta)data, con-
taining crucial information concerning study design, population size and 
age, sampling, analytics, and substances/biomarkers monitored, etc., 
amongst others. However, it is not able (yet) to quickly upload new data 
from data collections as the data collections themselves and the pre-
ceding study designs are lacking sufficient harmonisation. This limits 
easy and wider reuse and meta-analyses. There is for example currently 
not yet an optimal use of ontologies to facilitate linking different 
biomarker metabolites measured in different data collections but origi-
nating from the same parent substance to that parent substance. 
4. Remaining challenges to be addressed by development of the 
HBM registry system under the HBM GRF 
The current absence of harmonised study design templates makes 
searching HBM studies and their (meta)data cumbersome, and retro-
spective information validation processes time-consuming and often 
subject to errors. Data and metadata data harmonisation, at least from a 
retrospective point of view, requires access to a lot of information on 
each study including objectives, measured biomarkers and biological 
matrices, sampling methods, protocols, questionnaires, etc., which 
needs to be validated. Moreover, retrospective harmonisation processes 
are, to some extent, subjective processes and can thus present an 
inherent risk of biased (meta)data in a ‘post-hoc harmonised’ repository. 
In addition, researchers typically provide the data, including the 
(meta)data, quite some time after study completion. This can be prob-
lematic as other researchers and regulatory risk assessors, providing 
scientific advice to risk managers/policy makers, are often looking for 
fast and user-friendly access to information as well as protocols 
regarding planned and ongoing studies. Early-on registration of the plan 
for an HBM study, even in draft form, would enable other researchers to 
prepare for (re)using the new data once available. 
Another main issue is the lack of harmonisation in reporting of the 
chemical compounds investigated in HBM studies. Hundreds of non- 
endogenous compounds are found in HBM samples, some of them 
being known chemicals with a Chemical Abstract Services Registry 
Number (CAS RN), but many are unknown. Even known metabolites do 
not have CAS RNs as usually only the parent substance has been regis-
tered. Beyond this, even the use of a CAS RN for known compounds can 
be ambiguous (Williams and Yerin, 2013). Therefore, it is essential to 
harmonise how chemical compounds (parents and metabolites) are 
identified and findable (fulfil the FAIR criteria) in HBM studies. The 
InChI/InChIKey framework of IUPAC (IUPAC, 2018) is, to our knowl-
edge, the only system for unique identification of chemical substances 
with a known structure (including stereochemistry). Ontologies based 
on fragmentation in molecular structure might help in linking metabo-
lites to parent compounds. 
Although several environmental exposure studies have been regis-
tered in existing platforms (e.g., Study number NCT03440307 in the US 
ClinicalTrials database9), these platforms currently lack the design to 
enhance and optimize the dialogue between the scientific disciplines of 
epidemiology, HBM, toxicology and risk assessment. Most of these 
platforms merely make HBM-related studies findable. The harmo-
nisation of HBM would also be useful for prospective cohorts. Indeed, 
Fig. 1. HBM Global Registry Framework (HBM GRF).  
9 https://www.bbmri-eric.eu. 
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the proposed HBM GRF should promote a dialogue between organisers 
of HBM surveys and cohort studies since cohort data add a longitudinal 
component to better investigate exposure-effect-outcome relationships. 
Beyond this, a dialogue with the fields of toxicology and risk assessment 
must also be fostered. Toxicological data, preferably organized through 
AOPs (Adverse Outcome Pathways), help prioritise the most relevant 
effect biomarkers and adverse health outcomes to be investigated. Effect 
biomarkers are at the intersection of toxicology, epidemiology and 
HBM, and a more systematic use of effect biomarkers in HBM studies has 
been proposed (Zare Jeddi et al., 2020). Notwithstanding, given the 
complexity and diversity of effect biomarkers, a prospective harmo-
nisation of the type of biological samples collected (e.g., blood, urine), 
their processing (e.g., whole blood with or without RNA preservation, 
DNA isolation, serum, plasma, red blood cells, white blood cells) and 
their storage and biobanking are crucial for an optimal evaluation. 
Pourchet et al. (2020) in their recent publication on suspect and 
non-targeted screening of biomarkers in human matrices highlighted 
that harmonisation of quality assurance/quality control (QA/QC) 
Table 1 
Examples of existing platforms related to chemical monitoring data.  
Platform Coverage Funding Main aim(s) Limitation(s) 
IPCHEM (Information Platform for 
Chemical Monitoring) 
https://ipchem.jrc.ec.europa.eu/ 
Europe EC  • Assisting policy makers and scientists to 
discover and access chemical monitoring 
data on chemicals covering a range of 
matrices and media (environment, food and 
feed, human biomonitoring, indoor air, and 
products)  
• Hosting data currently not readily accessible 
(e.g., outcomes of research projects, off-line 
stored monitoring data)  
• Providing chemical monitoring data and 
information of defined quality in terms of 
spatial, temporal, methodological and 
metrological traceability  
• Differences in data quality  
• Differences in representativeness of 
populationsa  
• Discrepancies in reporting formats 
(harmonised for the essential fields 
but leaving room for data collection 
specific fields)  
• Only occurrence data from targeted, 
quantitative analyses 
Canada Open Government, 2020 
Canadian Health Measures Survey 
(CHMS) 
Human Biomonitoring Data for 
Environmental Chemicals 




Canada Canada government  • Present HBM results of the 5 cycles of the 
Canadian Health Measures Survey 
(2007–2017).  
• Tabulated CSV-downloadable results  








Not for profit network; 
self-funded by its 
members  
• Enhancing the exchange of information and 
collection of data on emerging 
environmental substances  
• Encouraging the validation and 
harmonisation of common measurement 
methods and monitoring tools  
• Ensuring that knowledge on emerging 
pollutants is maintained and developed by 
stimulating coordinated, interdisciplinary 
projects on problem-oriented research and 
knowledge transfer to address identified 
needs  
• Focus only on environment  
• Absence of information regarding 
human data 
BBMRI-ERIC (Biobanking and Bio- 
molecular Resources Research 
Infrastructure) 
https://www.bbmri-eric.eu/ 
Europe European Research 
Infrastructure 
Consortium funded by 
its members  
• Collecting and making available information 
about biobanks throughout Europe that are 
willing to share their data and/or samples, 
and to collaborate with other research 
groups  
• Only puts in contact people who 
search information on biobanks  
• Sample query processing missing 
Elixir community 
https://elixir-europe.org/ 
Europe National funding in 
each country (hubs) 
Managing and safeguarding the increasing 
volume of data being generated by publicly 
funded life sciences research  
• Currently mostly focussed on human 
endogenous compounds (DNA, 







Europe European Commission 
(DG Employment) 
Create a database and developing a model to 
estimate the occupational exposure for a list of 
hazardous chemicals in EU countries and in the 
EFTA/EEA countries.  
• Discontinued  
• Dedicated only to specific chemicals 
EC-European Commission; EFTA - European Free Trade Association; EEA – European Economic Area. 
a E.g., samples in one ‘national’ HBM cohort might be taken in 50 different locations in that country where another cohort in the same country might be taken at only 
10 different locations. 
Fig. 2. Time trend of monitoring data included in IPCHEM.  
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criteria and structure of reporting results appear necessary for better 
comparability of results produced by different laboratories (Pourchet 
et al., 2020). In addition, Galea et al. highlighted in their lessons learned 
from undertaking the HBM4EU chromates study that users must receive 
training and instruction to ensure that harmonised templates used to 
collect study data are populated correctly (Galea et al., 2021). A rigorous 
structure for reporting of screening-level monitoring data in environ-
mental matrices is already incorporated in the NORMAN Database 
System in the EMPODAT (Environmental Monitoring of POllutants 
DATabase) module (Dulio et al., 2020) and the first prototype for 
structured collection of non-target and suspect screening data has been 
developed in its Digital Sample Freezing Platform module (DSFP (Aly-
gizakis et al., 2019)). Another critical issue is how to deal with obser-
vations below the LOD (limit of determination) or LOQ (limit of 
quantification) in the statistical analyses and aggregation of the indi-
vidual data. Obviously, these are issues that could be included in the 
harmonisation efforts as part of the HBM GRF. 
In addition, policy support is not a strong component of existing 
platforms, which tend to function primarily as a repository of scientific 
information for researchers and not as an easily useable source of in-
formation for regulatory risk assessors, providing advice to risk man-
agers/policy makers. 
Existing platforms should be scrutinized for their strengths and 
weaknesses when developing the HBM GRF. Overall, user friendly web- 
based platforms would be key to facilitate further use of HBM (meta) 
data available or accessible via HBM GRF for regulatory risk assessment 
of chemicals and their mixtures. 
5. Aim and objectives of the HBM Global Registry Framework 
(HBM GRF) 
The aim of the HBM GRF is to make HBM research FAIR (Fig. 1). Only 
by doing so, the ethical imperative to make the most out of human 
volunteer data would be met. 
Based on crucial needs, a series of underlying objectives can be 
defined that, when accomplished, will increase wider use of HBM (meta) 
data. An HBM GRF is expected to be able to contribute to the following 
objectives: 
1. Creating an open-access web-based registry system that allows re-
searchers to register HBM studies.  
2. Improving data management infrastructure that will meet the FAIR 
principles by facilitating registrations of HBM studies. For example, 
assigning a unique reference ID for each study, which can be referred 
to in any research using data from that study. This would simplify the 
identification of studies generating new data or reusing data (orig-
inal study).  
3. Harmonising identifiers for chemical substances, including parent 
substances, metabolites, and effect biomarkers. Examples of effect 
biomarkers are hormones, specific DNA methylation, markers for 
gene expression of specific nuclear receptor, cholesterol, liver 
enzymes.  
4. Facilitating multidisciplinary interaction among research scientists, 
regulatory risk assessors and risk managers/policy makers in the 
domain of HBM, epidemiology, toxicology, and risk assessment. 
As an HBM GRF would benefit many stakeholders (national, EU, 
international), Table 2 summarises suggested intended audiences for the 
proposed HBM GRF including other regulatory frameworks and risk 
assessment processes, as well as for demonstrating regulatory efficacy 
(Louro et al., 2019). In addition, policy initiatives foreseen under the 
European Green Deal might benefit from an HBM GRF. A tabulated 
overview as prepared by the HBM4EU project indicates where HBM data 
could support directly and indirectly the European Green Deal (see 
Annex A, unpublished HBM4EU deliverable). 
6. How to make the HBM Global Registry Framework (HBM 
GRF) happen? 
In Europe there is an opportunity to bring the outlined concepts to 
fruition. In the coming years, the EU-wide research and innovation 
program PARC (Partnership for the Assessment of Risks from Chemicals) 
will run (see intermezzo overleaf). We think that this provides an 
excellent opportunity to investigate feasibility and options for devel-
opment of such a registry framework. The current organisations 
involved in the preparation of the Partnership represent 28 EU and non- 
EU countries and include ministries (for research, health, and environ-
ment), national and EU agencies and research organisations as well as 
academia and research institutions. We believe that this broad set-up is 
very well suited and capable of developing further the HBM GRF as 
advocated by the authors of in this article from various parts of the 
world. The stimulus could very well come from Europe under PARC. 
Global input during the process could be processed through the inter-
national PARC Advisory Board. Global contributions where possible 
along the process would be essential to ensure worldwide use of the 
HBM GRF to enhance registration of new and ongoing HBM studies e.g., 
Table 2 
Description of potential users and foreseen advantages of the HBM Global 
Registry Framework (HBM GRF).  
Users/Regulatory 
Frameworks 
More specific data/ 
information to be 










Analytical methods, QC/ 






describing some of the 
above; Statistical analysis 




Comparability of the data; 
Awareness of data 
requirements, 
Identification of gaps and 
needs for further research; 
Discovery of chemical 
analytical methods 
available; Use of HBM 















Comparability of the data; 
Data available to support 
modelling; Awareness for 
data requirements; 
Support for defining new 
HBM campaigns/ 
programmes. 
Regulatory risk assessors 
and competent 
authorities/REACH, 
OSH, Food safety 
Access to planned HBM- 
related studies 
(measuring exposure as 
well as effect biomarkers) 
also pointing at 
contextual data of 
studies; HBM results 
might enable setting of 
HBM guidance and limit 
values. 
Definition of priorities for 
RMMs (risk management 
measures) 
implementation; 
identification of new 
RMMs; Risk assessment 
options; Identification of 
needs for further 
regulatory actions to be 
supported by robust and 
available scientific 
knowledge. 
Industry and trade 
associations/REACH 
and OSH 
Access to planned HBM- 
related studies also 
pointing at contextual 
data of studies. 
Definition of priorities for 
RMMs implementation; 
identification of new 
RMMs.  
a The registries aimed at are not about results, but about the contextual data, 
and information on the study (sampling plan, study population, QC/QA, 
research hypotheses etc). 
b EU Regulation on Registration, Evaluation and Authorisation of CHemicals. 
c Occupational Safety and Health. 
M. Zare Jeddi et al.                                                                                                                                                                                                                            
International Journal of Hygiene and Environmental Health 238 (2021) 113826
7
NHANES in the USA, the CHMS in Canada, KNEHS in Korea and JECS in 
Japan. Additionally, support from and cooperation with UN, WHO and 
OECD would help global implementation of this initiative. 
PARC – Partnership for the Assessment of Risks from 
Chemicals 
PARC is an EU-wide research and innovation programme that will 
run 2022–2028. The Partnership will promote harmonisation of 
data and exchange between different actors (scientific commu-
nity, health agencies, regulators, policymakers etc.) and disci-
plines (e.g., exposure science, toxicology) to promote 
transparency, support risk assessment, and facilitate wider reuse 
of obtained data. To achieve this, it will build on existing data 
platforms included in or collaborating with the Partnership and 
contribute to extend their usability for risk assessors and man-
agers. It will ensure data and associated information is FAIR and 
addresses the GDPR (EU General Data Protection Regulation) 
related challenges for data exchange. Important will be that all 
relevant EU Agencies can duly contribute to and access relevant 
PARC activities and outputs, and the most relevant European 
Commission Directorates General will be involved as well. 
The Partnership will strive towards fostering European leadership 
at the international level for research and innovation in chemical 
risk assessment and will promote cooperation and collaboration 
across Europe and internationally. The Partnership will contribute 
to international fora, dealing with chemicals, pollution, and the 
SDGs (UN Sustainable Development Goals), such as the World 
Health Organisation (WHO) (e.g., International Programme on 
Chemical Safety IPCS Chemical Risk Assessment Network) and 
Strategic Approach to International Chemicals Management 
(SAICM), UN Environment Programme (UNEP) and OECD, 
dealing with chemicals, pollution, and the SDGs. Bilateral re-
lations with major international risk assessment agencies (e.g., U. 
S. Environmental Protection Agency) and research institutions (e. 
g., U.S. National Toxicology Program) will also be envisaged. 
Member States are already contributing as single entity to many of 
these networks. Collaboration of MS in the Partnership will 
strengthen the influence of the EU in addressing global challenges 
associated with chemical risk assessment and place the EU as the 
front runner of the international community in this area. 
Dialogue and collaboration with the international community is 
essential for mutual support and for the identification of needs and 
opportunities for harmonisation actions and development of tools 
that support the collaboration. Connecting this Partnership with 
the international community will foster the dissemination of re-
sults and will promote the importance of data and knowledge 
sharing among international networks. An international board 
consisting of experts from other international chemical risk 
assessment platforms, scientific advisory boards or scientific so-
cieties, or experts in related EU or international activities will 
contribute to ensuring the Partnership establishes links and dia-
logue with relevant international activities.   
7. Summary and conclusion 
Overall, we propose to develop an HBM Global Registry Framework 
(HBM GRF) aiming at harmonising the design and structuring the 
registration of HBM studies and by such, making the ultimate HBM 
(meta)data more FAIR (Findable, Accessible, Interoperable and Reus-
able). Consequently, this will improve the assessment, comparability 
and combination, reuse, and interpretation of HBM-study results. Pre-
paring HBM study protocols would be facilitated with such a web-based 
system as they would be based on digitised and harmonised templates. 
This would result in harmonised data entries into registries. 
The ultimate objective could be to make HBM (meta)data accessible 
in a virtual, federated, infrastructure, so that data with the right 
credentials become instantaneously accessible for human and machine 
interactions. Implementing the FAIR principles in the HBM domain 
could act as fundamental enabler for digital transformation in the 
environment and health domain. 
HBM GRF would facilitate the process of data creation and use to its 
final use and reuse (the data value chain). This is expected to better 
channel knowledge on the internal exposure of chemicals (exposure 
biomarkers) and early warnings of effects (effects biomarkers) in human 
samples into regulatory risk assessment and risk management (Burns 
et al., 2019). 
The HBM GRF would help to close the science to policy interface gap 
between scientific ambitions and regulatory and policy requirements 
resulting in an added value in protecting human health (Burns et al., 
2019).This knowledge transfer is of particular relevance for the Euro-
pean Chemicals Sustainability Strategy, which needs more and better 
exposure data, as well as in the scope of international conventions 
aiming to protect human health from chemical exposures. Creating the 
HBM GRF as proposed here would advance exposure science and would 
ultimately support a better protection of citizen’s health throughout the 
world (Fantke et al., 2020b). 
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The contents, including any opinions and/or conclusions expressed 
of this manuscript, are those of the authors alone and do not necessarily 
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employed. 
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